Elements CEO stepping down after 17 years leading credit union
Lisa Schlehuber has served as CEO of Indianapolis-based Elements Financial since 2005. She’ll retire from the role in April, the credit union announced Wednesday.
Eli Lilly and Co.
Articles
Lilly seeking FDA approval for new antibody it says works against omicron
In December, the U.S. government paused distribution of Lilly’s two previous antibodies, saying they did not appear effective against the omicron variant.
Lilly to invest $1B in new manufacturing plant, create 600 jobs in North Carolina
Lilly said it selected Concord, North Carolina, because of the manufacturing technology experience of the local labor force; its proximity to universities with strong science, technology, engineering and math programs; and its access to major transportation infrastructure.
Michigan AG seeks to investigate Eli Lilly for high insulin prices
Indianapolis-based Eli Lilly and Co., one of three primary U.S. insulin manufacturers, said it was “deeply disappointed by the false accusations and inaccurate claims” made by the attorney general.
FDA expected to sharply restrict use of monoclonal antibodies made by Lilly, Regeneron
The Food and Drug Administration is poised as soon as Monday to restrict two monoclonal antibodies, saying the COVID-19 treatments should not be employed in any states because they are ineffective against the dominant omicron variant, according to two senior administration health officials.
U.S. sends states monoclonal antibodies that might not work against omicron
The federal government has resumed shipping all three monoclonal antibody treatments—including one made by Indianapolis-based Eli Lilly and Co.—that are authorized for early-stage COVID-19 to states despite evidence that two might be ineffective against the omicron variant.
Eli Lilly inks R&D pact with Canadian pharma company
Indianapolis-based Eli Lilly and Co. will make an initial $50 million payment to Entos Pharmaceuticals. Entos also could receive up to $400 million in potential milestone payments, as well as royalties, for successful products.
Lilly resumes political contributions to Republicans who voted against certifying election
The pharmaceutical giant has quietly returned to making political contributions to 14 Republican lawmakers who voted against certifying the 2020 election results, according to a report issued Monday by watchdog group Accountable.US.
U.S. government puts pause on Lilly’s COVID antibody therapies
The U.S. Department of Health and Human Services cited new data that shows the therapies are unlikely to be effective against the Omicron variant.
Lilly’s osteoporosis drug faces generic challenge from Indian drugmaker
Eli Lilly’s blockbuster drug for osteoporosis, Forteo, could face generic competition from Indian drugmaker Sun Pharmaceuticals if the company can get a federal judge to declare that a Lilly patent won’t be infringed.
Omicron may sideline Lilly, Regeneron antibody drugs against COVID-19
The companies say they can quickly develop new omicron-targeting antibodies, but those aren’t expected to launch for at least several months.
Lilly, Chinese firm to pursue therapies for metabolic disorders
Indianapolis-based Eli Lilly and Co. has inked a research collaboration and licensing agreement with Regor Therapeutics Group that could be worth up to $1.5 billion.
Biden pledges savings on insulin, other drugs for Americans
The biggest policy change—a system for Medicare to negotiate prices for prescription drugs—won’t begin to deliver lower costs until 2025, and then only for a selected set of 10 medicines, as well as insulin products.
Feds buy another $1.29B worth of Lilly antibody treatment for COVID-19
The purchase will amount to 614,000 doses of two drugs, bamlanivimab and etesevimab, that make up the drug-cocktail infusion, Lilly said.
Federal court blocks drug pricing enforcement action against Lilly
The ruling from Senior Judge Sarah Evans Barker also hinted that Congress needs to address the problems with the 340B Drug Pricing Program.
Lilly misses earnings estimates but raises full-year outlook
Indianapolis-based Eli Lilly and Co. saw revenue in the third quarter increase 18 percent over the same period of 2020, to $6.77 billion.
Lilly CEO says letting Medicare negotiate drug prices would bring research cuts
“A cut [in drug prices] like is being proposed would have about a 40% reduction in our U.S. revenues,” Lilly CEO David Ricks said in a television interview this week with Gerry Dick on Inside Indiana Business, a division of IBJ Media.
Lilly’s antibody treatment gets another shot
The drugmaker’s COVID-19 treatment is back on the market after a two-month suspension, but the question is whether Lilly can grab market share from now-dominant Regeneron Pharmaceuticals.
U.S. government buys $330M worth of COVID-19 antibody doses from Lilly
Eli Lilly’s therapy has been shown to be highly effective against the delta variant, which is now the dominant strain of the coronavirus in the United States.
Lawsuit accuses Lilly of favoring millennials over older job applicants
Two former job applicants, aged 55 and 49, filed a proposed class-action lawsuit in U.S. District Court in Indianapolis on Wednesday, accusing the Indianapolis-based drug maker of age discrimination.